These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 29913223

  • 1. Tacrolimus has immunosuppressive effects on heavy/light chain pairs and free light chains in patients after heart transplantation: A relationship with infection.
    Lavríková P, Sečník P, Kubíček Z, Jabor A, Hošková L, Franeková J.
    Transpl Immunol; 2018 Oct; 50():43-47. PubMed ID: 29913223
    [Abstract] [Full Text] [Related]

  • 2. Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials.
    Lopez-Anglada L, Cueto-Felgueroso C, Rosiñol L, Oriol A, Teruel AI, Lopez de la Guia A, Bengoechea E, Palomera L, de Arriba F, Hernandez JM, Granell M, Peñalver FJ, Garcia-Sanz R, Besalduch J, Gonzalez Y, Martinez RB, Hernandez MT, Gutierrez NC, Puerta P, Valeri A, Paiva B, Blade J, Mateos MV, San Miguel J, Lahuerta JJ, Martinez-Lopez J, GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group.
    PLoS One; 2018 Oct; 13(9):e0203392. PubMed ID: 30192814
    [Abstract] [Full Text] [Related]

  • 3. Free light chain and intact immunoglobulin abnormalities in heart transplant recipients: Two year follow-up timelines and clinical correlations.
    Sečník P, Lavríková P, Hošková L, Malíková P, Jabor A, Franeková J.
    Transpl Immunol; 2017 Mar; 41():22-26. PubMed ID: 28167270
    [Abstract] [Full Text] [Related]

  • 4. Serum immunoglobulin free light chain and heavy/light chain measurements in POEMS syndrome.
    Wang C, Su W, Zhang W, Di Q, Duan MH, Ji W, Cao XX, Zhou DB, Li J.
    Ann Hematol; 2014 Jul; 93(7):1201-6. PubMed ID: 24482101
    [Abstract] [Full Text] [Related]

  • 5. Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen.
    Helmschrott M, Beckendorf J, Akyol C, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Ehlermann P, Bruckner T, Katus HA, Doesch AO.
    Drug Des Devel Ther; 2014 Jul; 8():1307-14. PubMed ID: 25246772
    [Abstract] [Full Text] [Related]

  • 6. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.
    Guethoff S, Stroeh K, Grinninger C, Koenig MA, Kleinert EC, Rieger A, Mayr T, von Ziegler F, Reichart B, Hagl C, Schramm R, Kaczmarek I, Meiser BM.
    J Heart Lung Transplant; 2015 May; 34(5):634-42. PubMed ID: 25701373
    [Abstract] [Full Text] [Related]

  • 7. Increased adherence eight months after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation.
    Doesch AO, Mueller S, Akyol C, Erbel C, Frankenstein L, Ruhparwar A, Ehlermann P, Dengler TJ, Katus HA.
    Drug Des Devel Ther; 2013 May; 7():1253-8. PubMed ID: 24174870
    [Abstract] [Full Text] [Related]

  • 8. The association of serum-free light-chain levels with markers of renal function.
    Erdem BK, Davran F, Yilmaz VT, Çetinkaya R, Akbas H.
    Ren Fail; 2015 Jul; 37(6):1057-60. PubMed ID: 26056734
    [Abstract] [Full Text] [Related]

  • 9. CYP3A5*3 and POR*28 genetic variants influence the required dose of tacrolimus in heart transplant recipients.
    Lesche D, Sigurdardottir V, Setoud R, Oberhänsli M, Carrel T, Fiedler GM, Largiadèr CR, Mohacsi P, Sistonen J.
    Ther Drug Monit; 2014 Dec; 36(6):710-5. PubMed ID: 24739669
    [Abstract] [Full Text] [Related]

  • 10. Does the calcineurin inhibitor have influence on cytomegalovirus infection in heart transplantation?
    Rodríguez-Serrano M, Sánchez-Lázaro I, Almenar-Bonet L, Martínez-Dolz L, Portolés-Sanz M, Rivera-Otero M, Salvador-Sanz A.
    Clin Transplant; 2014 Jan; 28(1):88-95. PubMed ID: 24325305
    [Abstract] [Full Text] [Related]

  • 11. Advantageous effects of immunosuppression with tacrolimus in comparison with cyclosporine A regarding renal function in patients after heart transplantation.
    Helmschrott M, Rivinius R, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Ehlermann P, Bruckner T, Katus HA, Doesch AO.
    Drug Des Devel Ther; 2015 Jan; 9():1217-24. PubMed ID: 25759566
    [Abstract] [Full Text] [Related]

  • 12. Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation.
    Guethoff S, Meiser BM, Groetzner J, Eifert S, Grinninger C, Ueberfuhr P, Reichart B, Hagl C, Kaczmarek I.
    Transplantation; 2013 Feb 27; 95(4):629-34. PubMed ID: 23423270
    [Abstract] [Full Text] [Related]

  • 13. [Analysis of the relationship of heavy/light chain pairs of immunoglobulin (Hevylite) to the results of gel electrophoresis and nefelometric examination of serum proteins at the time of multiple myeloma diagnosis].
    Ščudla V, Lochman P, Pika T, Zapletalová J, Minařík J, Bačovský J.
    Cas Lek Cesk; 2015 Feb 27; 154(6):292-302. PubMed ID: 26750626
    [Abstract] [Full Text] [Related]

  • 14. Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy.
    Rivinius R, Helmschrott M, Ruhparwar A, Schmack B, Klein B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Darche FF, Thomas D, Ehlermann P, Bruckner T, Katus HA, Doesch AO.
    Drug Des Devel Ther; 2015 Feb 27; 9():93-102. PubMed ID: 25552900
    [Abstract] [Full Text] [Related]

  • 15. Renal function in heart transplant patients after switch to combined mammalian target of rapamycin inhibitor and calcineurin inhibitor therapy.
    Helmschrott M, Rivinius R, Bruckner T, Katus HA, Doesch AO.
    Drug Des Devel Ther; 2017 Feb 27; 11():1673-1680. PubMed ID: 28652705
    [Abstract] [Full Text] [Related]

  • 16. Role of dendritic cells in the context of acute cellular rejection: comparison between tacrolimus- or cyclosporine A-treated heart transplanted recipients.
    John K, Dieterlen MT, Tarnok A, Garbade J, Bittner HB, Mohr FW, Barten MJ.
    Cytometry B Clin Cytom; 2014 Sep 27; 86(5):362-7. PubMed ID: 24668729
    [Abstract] [Full Text] [Related]

  • 17. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.
    Krämer BK, Klinger M, Vítko Š, Glyda M, Midtvedt K, Stefoni S, Citterio F, Pietruck F, Squifflet JP, Segoloni G, Krüger B, Sperschneider H, Banas B, Bäckman L, Weber M, Carmellini M, Perner F, Claesson K, Marcinkowski W, Ostrowski M, Senatorski G, Nordström J, Salmela K.
    Transplantation; 2012 Sep 15; 94(5):492-8. PubMed ID: 22858806
    [Abstract] [Full Text] [Related]

  • 18. Serum immunoglobulin free light chains and their association with clinical phenotypes, serology and activity in patients with IgG4-related disease.
    Martín-Nares E, Saavedra-González V, Fagundo-Sierra R, Santinelli-Núñez BE, Romero-Maceda T, Calderón-Vasquez K, Hernandez-Molina G.
    Sci Rep; 2021 Jan 19; 11(1):1832. PubMed ID: 33469111
    [Abstract] [Full Text] [Related]

  • 19. Clinical outcome in heart transplant recipients receiving everolimus in combination with dosage reduction of the calcineurin inhibitor cyclosporine A or tacrolimus.
    Fuchs U, Zittermann A, Ensminger SM, Schulz U, Gummert JF.
    Transpl Immunol; 2014 Aug 19; 31(2):87-91. PubMed ID: 24932812
    [Abstract] [Full Text] [Related]

  • 20. Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus-treated kidney transplant recipients.
    Włodarczyk Z, Wałaszewski J, Perner F, Vitko S, Ostrowski M, Bachleda P, Kokot F, Klinger M, Szenohradsky P, Studenik P, Navratil P, Asztalos L, Rutkowski B, Nagy KK, Hickey D.
    Ann Transplant; 2002 Aug 19; 7(3):28-31. PubMed ID: 12465429
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.